5 abstracts to watch out for at the ASCO22 meeting in Chicago
What to watch out for at AACR22 if you're interested in NK cells
Highlights from Day 1 of CART22, part 1
Continuing our ongoing series on immunosuppression and finding ways to overcome the hostile TME
What's hot in early preclinical development to watch out for?
A new emerging IO target of interest caught out attention, now what?
Update on the Gamma Delta T cell niche - what's new, what's up, and what's down?
Will CAR-NK cells follow CAR-T cell therapies and hit prime time?
Highlights (and lowlights) from the second day of the JPM Healthcare conference in San Francisco
As look at ways of targeting 𝞬𝝳 T cells, we may need to consider whether or not the situation is immunosuppressive or proliferative
What can we learn about gamma delta T cell cancer immunotherapy in China?
A look at the γδ T cell competitive landscape with cell therapies, antibodies and bispecifics in early stage development
Can we make novel allogeneic cell therapies with γδ T cells? We find out!
Can γδ T cells be employed as a therapeutic against cancer?
TC BioPharm are a cell therapy company to watch out for as they look towards an IPO in 2020
